Peptide Microarray Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 5.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Peptide Microarray Market Analysis
The peptide microarray market is expected to register a CAGR of 5% during the forecast period.
Peptide microarrays and protein, the emerging tools for clinical assays and proteomics, are high-throughput methods that decide the function of proteins on a large scale. The development of therapeutics required an accurate understanding of the role of the SARS-CoV-2 infection process and the progression of COVID-19. The field of proteomics is equipped with the technologies that are required to help face this challenge. In an article published in October 2020 in the Journal of Proteins and Proteomics, researchers have highlighted that developments in proteome technologies will not only accelerate progress in addressing the coronavirus pandemic but will also help to tackle the current COVID-19 crisis. A peptide microarray is used to study the binding properties of protein-protein interaction that comprises thousands of peptides in distinct patterns that will be used as a high throughput screening tool in biomedical science. For instance, in 2020, JPT peptide technologies accelerated the development of a broad collection of SARS-CoV-2 PepMix Peptide Pools that would span the most relevant antigens to address cellular immunity. JPT developed a Pan-Coronavirus RepliTope Peptide Microarray spanning the entire SARS-CoV-2 proteome and selected antigens of MERS-CoV, Common Cold Coronaviruses, and SARS-CoV for profiling humoral immune responses. Similarly in January 2020, PEPperPRINT launched the production of a proteome-wide peptide microarray covering the new coronavirus 2019-nCoV (COVID-19). It can be used to detect IgG and IgM antibody responses on the epitope level in patient sera for in-vitro diagnostic tests, diagnostics, and vaccine development. Thus, the market is exepcted to grow in the future.
Therefore the increasing burden of cancer and technological advancement are the major factors that are driving the studied market globally. Moreover, the rising prevalence of chronic diseases will further contribute to the peptide microarray market. According to the International Diabetes Federation Diabetes Atlas Tenth edition 2021, in 2021, around 537 million adults worldwide were found to have diabetes; the numbers are projected to grow to 643 million by 2030 and 783 million by 2045. The expected increase in the incidence of diabetes will increase the demand for diabetes diagnostic products and techniques, thus driving the market studied. Similarly, according to the Global Cancer Observatory (GLOBOCAN), Statistics 2020, there are 206,606,063 estimated prevalent cases of cancer in 5 years for all types of cancer in both sexes in Asia in 2020. It also reported 9,738,936 5-year prevalent cases of all types of cancer in males and about 10,867,127 cases in females. Such a high prevalence of cancer in the regions is generating the need for treatment therapies for cancer, thus driving the growth of the market studied. Furthermore, rising molecular-based diagnostics techniques demand with the advancement in the technology of diagnostic testing dominant the peptide microarray market. On February 21, 2020, the United States Food and Drug Administration updated its definition of a biologic to include chemically synthesized polypeptides greater than 40 amino acids but less than 100 amino acids in size (synthetic proteins) and synthetic peptides, 40 amino acids or less. Thus, the abovementioned factors are expected to increase market growth in the future.
However, reimbursement issues are expected to hinder the market growth.
Peptide Microarray Market Trends
This section covers the major market trends shaping the Peptide Microarray Market according to our research experts:
The Instrument Segment is Expected to Hold a Major Market Share in the Peptide Microarray Market
The instrument segment is expected to witness good growth in the market and is anticipated to show a similar trend over the forecast period, owing to technologically advanced peptide microarray products and various types of research in chronic disorders, such as cancer, autoimmune and infectious disease. For instance, PEPperPRIINT offers PEPperCHIP Standard Peptide Microarrays, which cover epitopes, antigens, and viral proteomics, and is widely used in various types of research (allergen, cancer, and signature discovery). Moreover, these are also used for antibody epitope mapping, biomarker discovery, immune monitoring, detection, and validation for protein interaction. For instance, JPT Peptide Technologies has a product PepStar Peptide Microarrays, which helps in enzyme profiling and identifies a substrate for orphan enzymes. The research and development of peptide products are increasing as they are cost-effective, efficient, and have lower toxicity. In September 2021, Nimble Therapeutics, a biotechnology company involved in the discovery and development of peptide therapeutics, reported that their strategic research collaboration with Incyte has been expanded to include the discovery of additional novel peptide therapies. Similarly, in November 2020, PEPperPRINT announced a partnership with Lucerna-Chem. Under a new distribution agreement, customers in Switzerland can now additionally avail of PEPperCHIP Peptide Microarray products and PEPperMAP Services through Lucerna-Chem. Thus, such agreements are expected to increase market growth by providing advance instruments in the region.
Thus, the abovementioned factors are expected to increase the market growth.
North America is Expected to Hold a Significant Share in the Market and Expected to do the Same in the Forecast Period
North America is expected to dominate the global peptide microarray market due to the increasing healthcare expenditure and the presence of a well-developed healthcare infrastructure. The growing chronic disease complexities are expected to enhance the demand for early diagnosis of the disease in hospitals, thereby increasing the use of diagnostic capabilities, which is expected to boost the usage of peptide microarrays. According to Globocan 2020, the estimated incidence of new cancer cases was 2,281,658, and the number of deaths was 612,390 due to cancer in 2020 in the United States. The most common cancers in the United States were breast, lung, prostate, and colon (101,809). The high cancer burden will surge the demand for peptide microarray. Moreover, rising molecular-based diagnostic techniques and increasing awareness among the population are also fueling the growth of the overall regional market. For instance, in June 2021, Nimble Therapeutics and RayzeBio reported that the companies entered a strategic collaboration to discover and develop novel peptide-based radiopharmaceuticals for the treatment of cancer. Similarly, in May 2021, Cipla stated the United States launch line-up in fiscal 2023, which analysts anticipate could include generic versions of Advair, Revlimid, and Abraxane. Partnered injectable peptide filings also bolster pipeline opportunities. Thus, such an increasing product pipeline in the region is expected to increase market growth.
Thus, the abovementioned factors are expected to increase the market growth.
Peptide Microarray Industry Overview
The peptide microarray market is moderately competitive and consists of several major players. Some companies currently dominating the market include Merck KGaA, ProImmune Ltd, JPT Peptide Technologies, Terra Universal Inc., and Arrayit Corporation among others.
Peptide Microarray Market Leaders
-
Merck KGaA
-
ProImmune Ltd
-
JPT Peptide Technologies
-
Terra Universal Inc
-
Arrayit Corporation
*Disclaimer: Major Players sorted in no particular order
Peptide Microarray Market News
- In June 2022, Ariceum Therapeutics launched with EUR 25M Series A to advance its lead asset, Satoreotide, for the treatment of low- and high-grade neuroendocrine cancers.
- In May 2022, Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd reported that the companies entered a definitive agreement under which Pfizer will acquire Biohaven, the maker of NURTEC ODT, an innovative dual-acting migraine therapy approved for both acute treatment and episodic prevention of migraine in adults.
Peptide Microarray Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Growing Burden of Chronic Diseases
- 4.2.2 Technological Advancements in Diagnostic Testing
-
4.3 Market Restraints
- 4.3.1 Reimbursement Issues
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Type
- 5.1.1 Instruments
- 5.1.2 Reagents
- 5.1.3 Services
-
5.2 By End User
- 5.2.1 Hospitals
- 5.2.2 Pharmaceutical and Biotechnology Companies
- 5.2.3 Research and Academic Institutes
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East & Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East & Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Arrayit Corporation
- 6.1.2 JPT Peptide Technologies
- 6.1.3 ProImmune Ltd
- 6.1.4 Merck KGaA
- 6.1.5 Terra Universal Inc.
- 6.1.6 PEPperPRINT
- 6.1.7 Thermo Fischer Scientific (Affymetrix)
- 6.1.8 Bio-Rad Laboratories
- 6.1.9 Terra Universal Inc.
- 6.1.10 LC Sciences
- 6.1.11 Grace Bio-Labs
- 6.1.12 Creative Biolabs
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityPeptide Microarray Industry Segmentation
As per the scope of the report, peptide microarrays are a powerful technology in the proteomics and clinical assays field that traces the binding activities, histone-modifying enzymes, and function of protein linkages on a large scale. Basically, a peptide microarray is a collection of peptides on glass or membrane, or plastic chip, which is also known as a peptide chip or peptide epitope microarray. Peptide microarrays are used to study the binding properties, activity, and function of protein-protein linkage in biology, diagnostics, antibody characterization, medicine, and pharmacology. The peptide microarray market is segmented by type (instruments, reagents, and services), end-user (hospitals, pharmaceutical, and biotechnology companies, research and academic institutes), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across the major regions globally. The report offers the values (USD million) for the above segments.
| By Type | Instruments | |
| Reagents | ||
| Services | ||
| By End User | Hospitals | |
| Pharmaceutical and Biotechnology Companies | ||
| Research and Academic Institutes | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East & Africa | GCC |
| South Africa | ||
| Rest of Middle East & Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Peptide Microarray Market Research FAQs
What is the current Global Peptide Microarray Market size?
The Global Peptide Microarray Market is projected to register a CAGR of 5% during the forecast period (2024-2029)
Who are the key players in Global Peptide Microarray Market?
Merck KGaA, ProImmune Ltd, JPT Peptide Technologies, Terra Universal Inc and Arrayit Corporation are the major companies operating in the Global Peptide Microarray Market.
Which is the fastest growing region in Global Peptide Microarray Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Peptide Microarray Market?
In 2024, the North America accounts for the largest market share in Global Peptide Microarray Market.
What years does this Global Peptide Microarray Market cover?
The report covers the Global Peptide Microarray Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Peptide Microarray Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
3D Laparoscopy Imaging Industry Report
Statistics for the 2024 3D Laparoscopy Imaging market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. 3D Laparoscopy Imaging analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
